Ultragenyx Announces Initiation of Phase 2 Study for Patients with Long-Chain Fatty Acid Oxidation Disorders

[GlobeNewswire] – NOVATO, Calif. — Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the first patient has … more

View todays social media effects on RARE

View the latest stocks trending across Twitter. Click to view dashboard

See who Ultragenyx is hiring next, click here to view